News Digging > Lifestyle > FDA Grants Pfizer’s RSV Vaccine Candidate Priority Review
FDA Grants Pfizer’s RSV Vaccine Candidate Priority Review
FDA Grants Pfizer's RSV Vaccine Candidate Priority Review,Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA

FDA Grants Pfizer’s RSV Vaccine Candidate Priority Review

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA